Robert Soiffer, MD, on other applications that IL-2 might have outside of treating chronic GVHD
Dr. Soiffer on other applications that IL-2 might have outside of treating chronic graft versus host disease (GVHD)
Robert Soiffer, MD, on some of the innovative approaches to treating chronic GVHD
Dr. Soiffer on some of the innovative approaches to treating chronic graft versus host disease (GVHD)
Robert Soiffer, MD, discusses current treatments available for chronic GVHD
Dr. Soiffer discusses current treatments available for chronic graft versus host disease (GVHD)
Robert Soiffer, MD, explains GVHD and some of the complications that come along with it
Dr. Soiffer explains chronic graft versus host disease (GVHD) and some of the complications that come along with it
David S. Siegel, MD, discusses how stem cell transplant figures into MM treatment algorithms
Dr. Siegel discusses how autologous stem cell transplant figures into Multiple Myeloma treatment algorithms
Debu Tripathy, MD, on immunotherapies being studied for treatment of metastatic breast cancer
Dr. Tripathy, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, reflects on how immunotherapies are being studied and possibly integrated into the treatment of metastatic breast cancer
Debu Tripathy, MD, shares his impressions of the MONALEESA-2 study
Dr. Tripathy, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, offers his take on the secondary analysis of the MONALEESA-2 study
Debu Tripathy, MD, regarding the results of the MONARCH-2 study
Dr. Tripathy, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, elaborates on how the results of the MONARCH-2 study presented at ASCO 2017 will impact the way he treats breast cancer patients
Mohammad Jahanzeb, MD, FACP, on immunotherapy and treatment of metastatic breast cancer
Dr. Jahanzeb, Professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, describes how immunotherapies are being studied and possibly integrated into the treatment of metastatic breast cancer
Mohammad Jahanzeb, MD, FACP, discusses the results of the MONARCH-2 study presented at ASCO
Dr. Jahanzeb, Professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, speculates on how the results of the MONARCH-2 study presented at ASCO 2017 could change the way we treat breast cancer patients
Mohammad Jahanzeb, MD, FACP, on the impact of the APHINITY study presented at ASCO
Dr. Jahanzeb, Professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, describes how the APHINITY study could impact the treatment of adjuvant breast cancer
Neelima Denduluri, MD, discusses exciting new approaches to treating breast cancer
Dr. Denduluri, Associate Chair, US Oncology Research Virginia Cancer Specialists, comments on the most exciting new approaches to treating breast cancer
Neelima Denduluri, MD, describes how CDK 4/6 inhibitors impact breast cancer treatment
Dr. Denduluri, Associate Chair, US Oncology Research, Virginia Cancer Specialists, elaborates on how CDK 4/6 inhibitors are changing the way breast cancer is treated, and how to differentiate between the various inhibitors
Neelima Denduluri, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer
Dr. Denduluri, Associate Chair, US Oncology Research Virginia Cancer Specialists, explains how the APHINITY study could impact the treatment of adjuvant breast cancer
Neelima Denduluri, MD, discusses the results of the MONARCH-2 study presented at ASCO
Dr. Denduluri, Associate Chair, US Oncology Research Virginia Cancer Specialists, discusses the results of the MONARCH-2 study presented here at ASCO
Real-World Evidence: Can It Drive Differentiation and Demonstrate 'Value'?
ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ASCO 2017 to discuss how real-world evidence can demonstrate value.
Real-World Evidence Today and Tomorrow: The Role of Key Stakeholders
ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ASCO 2017 to talk about the changing role of real-world evidence.
Real-World Evidence Compared to Randomized Clinical Trials
ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ASCO 2017 to talk about the changing role of real-world evidence.
Real-World Evidence as a Mechanism for Patient-Centric Care
ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ASCO 2017 to talk about the changing role of real-world evidence.
Practical Issues When Treating With Immunotherapy
ZS’s Sharon Karlsberg sat down with Dr. Suzanne Topalian, associate director of the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, at ASCO 2017 to talk about where we are headed with immunotherapy in oncology.
Beyond PD-L1: In Search of Better Biomarkers
ZS’s Sharon Karlsberg sat down with Dr. Suzanne Topalian, Associate Director of the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, at ASCO 2017 to talk about where we are headed with immunotherapy in oncology.
Evolving Immunotherapy Combinations
At ASCO 2017, ZS’s Sharon Karlsberg and Dr. Suzanne Topalian, associate director of the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, discuss evolving immunotherapy combinations.
Aref Al-Kali, MD, regarding the Leukostat test in conjunction with midostaurin
Dr. Al-Kali, Acute Leukemia and Chronic Myeloid Disorders, Mayo Clinic, on whether physicians will adopt the Leukostat test, which was approved in conjunction with midostaurin
Barbara Burtness, MD, on chemotherapy and post-operative radiation in H&C cancers
Dr. Burtness, Disease Aligned Research Team Leader, Head and Neck Cancers Program Co-Director, Developmental Therapeutics Research Program, Yale Cancer Center, discusses how chemotherapy should be dosed when given with post-operative radiation in head and neck cancers
Mary Jo Fidler, MD, FASCO, considers the biomarker challenges when treating SCLC
Dr. Fidler, Associate Professor, Medical Oncology, Rush University Medical Center, elaborates on the challenges associated with biomarkers when treating small cell lung cancer
Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC
Dr. Fidler, Associate Professor, Medical Oncology, Rush University Medical Center, speculates on the future of immunotherapy combinations when treating small cell lung cancer
Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC
Dr. Fidler, Associate Professor, Medical Oncology, Rush University Medical Center, describes how immunotherapies should be integrated into the treatment of small cell lung cancer
David Siegel, MD, PhD, on pomalidomide as an effective salvage therapy for MM patients
Dr. Siegel, Chief, Multiple Myeloma, John Theurer Cancer Center, elaborates on whether pomalidomide can be an effective salvage therapy for multiple myeloma patients progressing on lenalidomid
David Siegel, MD, PhD, considers the effectiveness of CAR T-cell therapy in treating MM
Dr. Siegel, Chief, Multiple Myeloma, John Theurer Cancer Center, elaborates on the effectiveness of CAR T-cell therapy in treating multiple myeloma patients
David Siegel, MD, PhD, on pembrolizumab and lenalidomide in multiple myeloma treatment
Dr. Siegel, Chief, Multiple Myeloma, John Theurer Cancer Center, considers whether combining pembrolizumab and lenalidomide is effective when managing multiple myeloma patients
Nicholas J. Vogelzang, MD, FASCO, FACP, on identifying the best patients for Zytiga versus Xtandi
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, describes how to identify the right patient for Zytiga or Xtandi
George Simon, MD, FACP, FCCP, on the Checkmate 032 & CTONG 1104 NSCLC studies presented at ASCO
Dr. Simon, Professor of Medicine and Oncology, MD Anderson Cancer Center, shares his impressions of the Checkmate 032 and CTONG 1104 NSCLC studies presented at ASCO 2017
George Simon, MD, FACP, FCCP, regarding the most impactful clinical studies on lung cancer at ASCO
Dr. Simon, Professor of Medicine and Oncology, MD Anderson Cancer Center, describes the clinical studies presented at ASCO 2017 that could be most impactful for lung cancer patients
Jeffrey Meyerhardt, MD, discusses BRAF+ mutation metastatic CRC and vemurafenib
Dr. Meyerhardt, Clinical Director, Gastrointestinal Cancer Center, Associate Professor of Medicine, Harvard Medical School, on adopting vemurafenib in BRAF+ mutation metastatic CRC
Jeffrey Meyerhardt, MD, offers opinion on the effectiveness of SIRT in treatment of metastatic HCC
Dr. Meyerhardt, Clinical Director, Gastrointestinal Cancer Center, Associate Professor of Medicine, Harvard Medical School, on whether SIRT is effective in the treatment of metastatic HCC
Jeffrey Meyerhardt, MD, regarding the optimal duration of therapy in stage III colon cancer patients
Dr. Meyerhardt, Clinical Director, Gastrointestinal Cancer Center, Associate Professor of Medicine, Harvard Medical School, discusses the optimal duration of therapy in stage III colon cancer
Jeffrey Meyerhardt, MD, on how immunotherapies are being studied in gastric & esophageal cancers
Dr. Meyerhardt, Clinical Director, Gastrointestinal Cancer Center, Associate Professor of Medicine, Harvard Medical School, elaborates on how immunotherapies are being studied in gastric and esophageal cancers
Christopher Logothetis, MD, offers opinion on the efficacy of the AR-V7 test
Dr. Logothetis, Chairman & Professor, Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, discusses whether the AR-V7 test is ready for prime time
Christopher Logothetis, MD, explains how he identifies the right patients for Zytiga versus Xtandi
Dr. Logothetis, Chairman & Professor, Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, elaborates on how he identifies the right patient for Zytiga or Xtandi
Christopher Logothetis, MD, regarding CHAARTED, STAMPEDE, and LATITUDE data from ASCO 2017
Dr. Logothetis, Chairman & Professor, Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, elaborates on the data from CHAARTED, STAMPEDE and LATITUDE studies presented at ASCO 2017
Christopher Logothetis, MD, speculates on the cost implications of abiraterone
Dr. Logothetis, Chairman & Professor, Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, discusses potential cost implications if abiraterone becomes the standard of care
Christopher Logothetis, MD, on why the results of the LATITUDE study will be practice changing
Dr. Logothetis, Chairman & Professor, Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, explains how the results of the LATITUDE study will change
Edward Kim, MD, provides insight on how to use the PD-L1 biomarker to direct therapy
Dr. Kim, Medical Oncologists, Levine Cancer Institute, shares how he is using the PD-L1 biomarker to help determine which patients to treat with pembrolizumab
Edward Kim, MD, describes how immunotherapy combinations will be used in the near future
Dr. Kim, Medical Oncologists, Levine Cancer Institute, explains how immunotherapy combinations will be used in the near term and what patients can expect from these combinations
Edward Kim, MD, comments on gefitinib versus vinorelbine-cisplatin as adjuvant treatment in NSCLC
Dr. Kim, Medical Oncologists, Levine Cancer Institute, compares gefitinib versus vinorelbine-cisplatin ad adjuvant treatment in stage II-IIIA (N1 N2) NSCLC with EGFR-activating mutation
Edward Kim, MD, on anti-PD-L1/PD-1 combination therapies in treatment of lung cancer
Dr. Kim, Medical Oncologists, Levine Cancer Institute, explains how anti-PD-L1/PD-1 therapies are being combined with chemotherapy and targeted therapies to treat lung cancer
Edward Kim, MD, offers his opinion on the biggest news in lung cancer before and during ASCO 2017
Dr. Kim, Medical Oncologists, Levine Cancer Institute, describes the advances in lung cancer leading up to and during ASCO 2017
Howard Hochster, MD, discusses the optimal duration of FOLFOX therapy in stage III colon cancer
Dr. Hochster, Associate Director for Clinical Services, Yale Cancer Center, on whether stage III colon cancer patients should be treated with 3 months of 6 months of FOLFOX therapy
Howard Hochster, MD, on the impact of SWOG 1406 in treating BRAF mutation positive CRC patients
Dr. Hochster, Associate Director for Clinical Services, Yale Cancer Center, describes his approach to treating BRAF mutation positive CRC patients as a result of the recent SWOG 1406 study
Richard Goldberg, MD, FASCO, on the new FDA indication for pembrolizumab
Dr. Goldberg, Medical Director, West Virginia University Cancer Institute, provides opinion on the new FDA indication for pembrolizumab in tumor-agnostic MSI-high patients
Richard Goldberg, MD, FASCO, shares his impression of the adjuvant biliary tract study at ASCO 2017
Dr. Goldberg, Medical Director, West Virginia University Cancer Institute, offers opinion on the adjuvant biliary tract study presented at ASCO 2017
Richard Goldberg, MD, FASCO, regarding the optimal duration of therapy in stage III colon cancer
Dr. Goldberg, Medical Director, West Virginia University Cancer Institute, discusses the optimal duration of therapy in a stage III colon cancer patient
Howard Hochster, MD, explains the impact of immunotherapies on gastric GE junction cancers
Dr. Hochster, Associate Director for Clinical Services, Yale Cancer Center, offers opinion on how immunotherapies will impact the treatment of gastric GE junction cancers
Howard Hochster, MD, regarding the new peri-operative regimen FLOT for gastric cancer
Dr. Hochster, Associate Director for Clinical Services, Yale Cancer Center, shares his impression of the new peri-operative regimen FLOT compared to ECX for gastric cancer patients
Richard Goldberg, MD, FASCO, defines “high-risk” and “low-risk” stage III colon cancer patients
Dr. Goldberg, Medical Director, West Virginia University Cancer Institute, differentiates between “high-risk” and “low-risk” in a stage III colon cancer patient
Patricia Goldsmith describes new patient-focused initiatives presented at ASCO 2017
Patricia Goldsmith, CEO, Cancer Care, regarding new information on patient-focused initiatives coming out of ASCO 2017
Patricia Goldsmith discusses the tools available for cancer patients on their journey
Patricia Goldsmith, CEO, Cancer Care, describes what tools cancer patients should have as they progress through treatment
Patricia Goldsmith shares what CancerCare is doing to help patients with financial toxicity
Patricia Goldsmith, CEO, Cancer Care, elaborates on what CancerCare is doing to help patients combat financial toxicity
Nancy Dawson, MD, compares the side effect profiles of abiraterone and chemotherapy
Dr. Dawson, Professor of Medicine, Lombardi Cancer Center, Georgetown University Hospital, examines the side effect profile of abiraterone and the side effect profile of chemotherapy
Nancy Dawson, MD, on how hormone-sensitive advanced prostate cancer should be treated
Dr. Dawson, Professor of Medicine, Lombardi Cancer Center, Georgetown University Hospital, provides perspective on how we should treat hormone-sensitive advanced prostate cancer as a result of the studies presented at ASCO 2017
Nancy Dawson, MD, regarding the STAMPEDE study presented at ASCO 2017
Dr. Dawson, Professor of Medicine, Lombardi Cancer Center, Georgetown University Hospital, elaborates on the importance of the STAMPEDE study
Nancy Dawson, MD, shares her impressions of the LATITUDE study
Dr. Dawson, Professor of Medicine, Lombardi Cancer Center, Georgetown University Hospital, offers opinion on the LATITUDE study presented at ASCO 2017
Barbara Burtness, MD, on bevacizumab and chemotherapy for treatment of metastatic H&C cancers
Dr. Burtness, Disease Aligned Research Team Leader, Head and Neck Cancers Program Co-Director, Developmental Therapeutics Research Program, Yale Cancer Center, considers whether Avastin (bevacizumab) should be added to chemotherapy for the treatment of metastatic head and neck cancers
Barbara Burtness, MD, considers whether H&N patients should be routinely tested for PD-L1
Dr. Burtness, Disease Aligned Research Team Leader, Head and Neck Cancers Program Co-Director, Developmental Therapeutics Research Program, Yale Cancer Center, offers opinion on whether H&N patients should be routinely tested for PD-L1
Barbara Burtness, MD, discusses immunotherapies and treatment of head and neck cancers
Dr. Burtness, Disease Aligned Research Team Leader, Head and Neck Cancers Program Co-Director, Developmental Therapeutics Research Program, Yale Cancer Center, regarding how immunotherapies are being integrated into the treatment of H&N cancers
Barbara Burtness, MD, shares her thoughts on the results of the LUX head and neck 2 study
Dr. Burtness, Disease Aligned Research Team Leader, Head and Neck Cancers Program Co-Director, Developmental Therapeutics Research Program, Yale Cancer Center, elaborates on the recently presented results of the LUX head and neck 2 study
Phil Bonomi, MD, on immunotherapy for treatment of SCLC and mesothelioma
Phil Bonomi, MD, explains how immunotherapies are being integrated into treatment of SCLC and mesothelioma
Thaddeus Beck, MD, FACP, on how Watson for Clinical Trials Matching can increase practice efficiency
Dr. Beck, Medical Oncologist, Highlands Oncology Group, Fayetteville, Arkansas, describes how the Watson for Clinical Trials Matching tool will increase workflow efficiency regarding clinical trials in community oncology practices
Thaddeus Beck, MD, FACP, explains how Watson for Clinical Trials Matching operates
Dr. Beck, Medical Oncologist, Highlands Oncology Group, Fayetteville, Arkansas, elaborates on how the Watson for Clinical Trials Matching tool operates
Thaddeus Beck, MD, FACP, shares his experience working with Watson for Clinical Trials Matching
Dr. Beck, Medical Oncologist, Highlands Oncology Group, Fayetteville, Arkansas, discusses his study examining his experience with the Watson for Clinical Trials Matching tool
Phil Bonomi, MD, offers opinion on whether MET inhibitors are effective in metastatic NSCLC
Dr. Bonomi, Professor of Medicine, Rush University Medical Center, discusses the efficacy of MET inhibitors in metastatic NSCLC
Noa Biran, MD, on what physicians should be aware of when sequencing agents in treating MM
Dr. Biran, Associate Professor, Hematologists/Oncologists, Multiple Myeloma Division, John Theurer Cancer Center, describes what physicians should be aware of when sequencing agents in the treatment of multiple myeloma
Noa Biran, MD, offers opinion on how personalized medicine will impact treatment of multiple myeloma
Dr. Biran, Associate Professor, Hematologists/Oncologists, Multiple Myeloma Division, John Theurer Cancer Center, explains how she expects personalized medicine to impact the treatment of multiple myeloma
Noa Biran, MD, shares how immunotherapies are being integrated into MM treatment algorithms
Dr. Biran, Associate Professor, Hematologists/Oncologists, Multiple Myeloma Division, John Theurer Cancer Center, describes how immunotherapies are being integrated into multiple myeloma treatment algorithms
Noa Biran, MD, reviews the data from ASCO regarding induction of newly diagnosed MM patients
Dr. Biran, Associate Professor, Hematologists/Oncologists, Multiple Myeloma Division, John Theurer Cancer Center, discusses the data presented at ASCO 2017 regarding induction of newly diagnosed MM patients
Jack West, MD, shares his outlook on IDO inhibitors for treatment of lung cancer
Dr. West, Swedish Cancer Institute, Medical Director, Thoracic Oncology Program, elaborates on the future of IDO inhibitors for the treatment of lung cancer patients
Jack West, MD, on what we know about durvalumab in treatment of stage 3 NSCLC
Dr. West, Swedish Cancer Institute, Medical Director, Thoracic Oncology Program, describes what we know about durvalumab and how it may or may not fill an unmet need in stage 3 NSCLC
Jack West, MD, considers the relevance of testing for PD-L1
Dr. West, Swedish Cancer Institute, Medical Director, Thoracic Oncology Program, on whether or not it is relevant to test for PD-L1 with an approval without the PD-L1 biomarker
Jack West, MD, discusses possible immunotherapy combination treatments in the near future
Dr. West, Swedish Cancer Institute, Medical Director, Thoracic Oncology Program, on how he expects immunotherapies to be combined in the near future, and what oncologists can hope to achieve from these combinations
Jack West, MD, on anti-PD-L1/PD-1 therapy in combination with chemotherapy & targeted therapies
Dr. West, Swedish Cancer Institute, Medical Director, Thoracic Oncology Program, describes how anti-PD-L1/PD-1 therapies are combined with chemotherapy and targeted therapies to treat lung cancer
Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the potential of the AR-V7 test
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, considers the AR-V7 test and whether or not it is ready for prime time
Nicholas J. Vogelzang, MD, FASCO, FACP, considers data from CHAARTED, STAMPEDE, and LATTITUDE
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, offers perspective on CHAARTED and STAMPEDE data and compares it with LATTITUDE
Nicholas J. Vogelzang, MD, FASCO, FACP, speculates on the cost implications of abiraterone
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, elaborates on the cost implications if abiraterone becomes the new standard of care
Nicholas J. Vogelzang, MD, FASCO, FACP, on the practice-changing results of the LATITUDE study
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, comments on how the results of the LATITUDE study presented at ASCO 2017 will impact practices
Jeff Sharman, MD, offers perspective on CAR T-cell therapies for the treatment of NHL
Dr. Sharman, Medical Director, Hematology Research, The US Oncology Network, Willamette Valley Cancer Center, on CAR T-cell therapies as a promising treatment option for NHL
Jeff Sharman, MD, shares results of the GENUINE phase 2 study presented at ASCO 2017
Dr. Sharman, Medical Director, Hematology Research, The US Oncology Network, Willamette Valley Cancer Center, discusses the results of the GENUINE phase 3 high risk relapsed CLL study he presented at ASCO
Jeff Sharman, MD, comments on emerging trends in CLL management
Dr. Sharman, Medical Director, Hematology Research, The US Oncology Network, Willamette Valley Cancer Center, discusses what he sees as emerging trends in CLL management
Randall Oyer, MD, describes how ACCC is supporting practices that are participating in OCM
Dr. Oyer, Treasurer, Association of Community Cancer Centers, Medical Director, Ann B. Barshinger Cancer Institute, Lancaster General Health, outlines how ACCC is supporting practices that participate in OCM
Randall Oyer, MD, reveals the challenges and solutions his practice is finding as a result of OCM
Dr. Oyer, Treasurer, Association of Community Cancer Centers, Medical Director, Ann B. Barshinger Cancer Institute, Lancaster General Health, explains the challenges and solutions that his practice is finding as a result of participating in OCM
Randall Oyer, MD, shares major themes emerging from the OCM
Dr. Oyer, Treasurer, Association of Community Cancer Centers, Medical Director, Ann B. Barshinger Cancer Institute, Lancaster General Health, lists the major themes that are emerging from the OCM
Randall Oyer, MD, on how OCM is helping the healthcare system transition from volume to value
Dr. Oyer, Treasurer, Association of Community Cancer Centers, Medical Director, Ann B. Barshinger Cancer Institute, Lancaster General Health, offers opinion on how OCM is helping the healthcare system transition from volume to value
Kathryn Kolibaba, MD, lists key takeaways from the lymphoma oral session at ASCO 2017
Dr. Kolibaba, Associate Chair, Hematology, US Oncology Research, discusses the general takeaways of the lymphoma oral session presented at ASCO and what it means for practicing physicians
Kathryn Kolibaba, MD, shares the results of the MAGNIFY study presented at ASCO
Dr. Kolibaba, Associate Chair, Hematology, US Oncology Research, elaborates on the results of the MAGNIFY study specific to the high risk population in indolent NHL patients
Mohammad Jahanzeb, MD, FACP, comments on the differences between CDK 4/6 inhibitors
Dr. Jahanzeb, Professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, explains the differences between the CDK 4/6 inhibitors in development
Leonard Saltz, MD, reflects on intriguing CRC clinical data presented at ASCO 2017
Dr. Saltz, Chief, Gastrointestinal Oncology Service, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, describes the most interesting clinical data related to CRC presented at ASCO 2017
Leonard Saltz, MD, shares thoughts on how to control rising drug prices without impacting value
Dr. Saltz, Chief, Gastrointestinal Oncology Service, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, contemplates how to control rising drug prices without sacrificing value and innovation
Leonard Saltz, MD, offers opinion on the optimal duration of adjuvant chemotherapy in colon cancer
Dr. Saltz, Chief, Gastrointestinal Oncology Service, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses the role and duration of adjuvant chemotherapy in colon cancer treatment
Leonard Saltz, MD, elaborates on what interventions could help alleviate financial toxicity
Dr. Saltz, Chief, Gastrointestinal Oncology Service, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, considers what intervention methods can potentially help alleviate financial toxicity
Leonard Saltz, MD, on how to begin the conversation with patients about financial toxicity
Dr. Saltz, Chief, Gastrointestinal Oncology Service, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses how and when to start the conversation with patients about financial toxicity
Philip Philip, MD, on the lenvatinib data in patients with unresectable HCC presented at ASCO 2017
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, describes the lenvatinib data presented at ASCO 2017 in patients with unresectable hepatocellular carcinoma
Philip Philip, MD, considers the benefits of immunotherapy in treating gastrointestinal cancer
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, describes the benefits of using immunotherapy in patients with gastric or gastroesophageal junction tumors
Philip Philip, MD, shares his impression of the capcitabine data in biliary cancers
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, discusses capcitabine data in biliary cancer
Philip Philip, MD, reflects on the impact of PEGPH20 in met pancreatic cancer
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, offers opinion on how PEGPH20 in met pancreatic cancer will impact the care of patients
Philip Philip, MD, on what we’ve learned about the duration of therapy in the adjuvant CRC setting
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, elaborates on what we know about duration of therapy in the adjuvant CRC setting
Daniel Petrylak, MD, offers recommendations for bladder cancer patients
Dr. Petrylak, Professor of Medicine, Director, GU Oncology Program, Yale School of Medicine, discusses which test(s) bladder cancer patients should get as part of their work up
Daniel Petrylak, MD, on treating bladder cancer patients progressing on checkpoint inhibitors
Dr. Petrylak, Professor of Medicine, Director, GU Oncology Program, Yale School of Medicine, elaborates on what to do with bladder cancer patients who are progressing on checkpoint inhibitors
Daniel Petrylak, MD, discusses the role of checkpoint inhibition therapy in urothelial carcinoma
Dr. Petrylak, Professor of Medicine, Director, GU Oncology Program, Yale School of Medicine, describes the role of checkpoint inhibition therapy in urothelial carcinoma
Daniel Petrylak, MD, on prostate cancer guidelines and the results of the LATITUDE study
Dr. Petrylak, Professor of Medicine, Director, GU Oncology Program, Yale School of Medicine, offers perspective on updating prostate cancer guidelines based on the results of the LATITUDE study presented at ASCO 2017
Andrew Pecora, MD, FACP, CPE, shares how COTA and IBM Watson are working together
Dr. Pecora, President, Physician Enterprise, Chief Innovative Officer, Hackensack Meridian Health, John Theurer Cancer Center, offers details on how COTA and IBM Watson are working together to identify and eliminate adverse variants
Andrew Pecora, MD, FACP, CPE, on the implications of healthcare and reimbursement reform
Dr. Pecora, President, Physician Enterprise, Chief Innovative Officer, Hackensack Meridian Health, John Theurer Cancer Center, outlines the implications of healthcare and reimbursement reform on technologies and innovations coming out of ASCO 2017
Andrew Pecora, MD, FACP, CPE, describes the movement to value-based reimbursement
Dr. Pecora, President, Physician Enterprise, Chief Innovative Officer, Hackensack Meridian Health, John Theurer Cancer Center, elaborates on the tools oncologists need as they move from fee for service to value-based reimbursement
Andrew Pecora, MD, FACP, CPE, on healthcare reform and the move from volume to value in oncology
Dr. Pecora, President, Physician Enterprise, Chief Innovative Officer, Hackensack Meridian Health, John Theurer Cancer Center, shares his thoughts on healthcare reform and the movement from volume to value in oncology
Debra Patt, MD, MPH, MBA, on establishing a more informatics enabled oncology practice
Dr. Patt, Vice President for Texas Oncology, shares her thoughts on creating a more informatics enabled oncology practice
Debra Patt, MD, MPH, MBA, speculates on upcoming changes in the 340B program
Dr. Patt, Vice President of Texas Oncology, discuses potential changes in the 340B program
Debra Patt, MD, MPH, MBA, comments on how she sees the new administration addressing drug costs
Dr. Patt, Vice President of Texas Oncology, discusses how she sees the new administration addressing drug costs
Debra Patt, MD, MPH, MBA, offers opinion on incorporating liquid biopsy into patient management
Dr. Patt, Vice President of Texas Oncology, discusses incorporating liquid biopsy into her patient management algorithms
Debra Patt, MD, MPH, MBA, on the repercussions if utilization management isn’t used properly
Dr. Patt, Vice President of Texas Oncology, describes the downside if utilization management isn’t used properly
Debra Patt, MD, MPH, MBA, explains the concept and importance of utilization management
Dr. Patt, Vice President of Texas Oncology, elaborates on the various forms of utilization management and why utilization management is important
Andrew Norden, MD, speculates on the future of Watson for oncology
Dr. Norden, Deputy Chief Health Officer, IBM Watson Health, describes new developments we can expect over the next several years that will make Watson even more valuable and accessible to oncologists
Andrew Norden, MD, on how physicians can take advantage of Watson’s expanding library of tumor types
Dr. Norden, Deputy Chief Health Officer, IBM Watson Health, explains how physicians can utilize Watson’s library of tumor types and what it takes to add a new tumor type to that library
Andrew Norden, MD, describes the clinical utility of Watson for oncology
Dr. Norden, Deputy Chief Health Officer, IBM Watson Health, elaborates on the data being presented at ASCO 2017 demonstrating clinical utility of Watson for oncology
Kathryn Kolibaba, MD, describes the results of the BRIGHT study in front-line indolent NHL patients
Dr. Kolibaba, Associate Chair, Hematology, US Oncology Research, offers insight on the BRIGHT study in front-line indolent NHL patients
Sundar Jagannath, MD, on what we should know when sequencing agents in treating multiple myeloma
Dr. Jagannath, Director of Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, provides feedback on what physicians should know when sequencing agents in the treatment of multiple myeloma
Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma
Dr. Jagannath, Director of Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, comments on how he expects personalized medicine to impact the treatment of multiple myeloma
Sundar Jagannath, MD, on immunotherapies and multiple myeloma treatment algorithms
Dr. Jagannath, Director of Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, elaborates on how immunotherapies are being integrated into multiple myeloma treatment algorithms
Sundar Jagannath, MD, discusses promising data from ASCO regarding multiple myeloma
Dr. Jagannath, Director of Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, outlines the most promising clinical data regarding the treatment of multiple myeloma presented at ASCO 2017
Robert Figlin, MD, explains how checkpoint inhibitors are changing the way RCC is treated
Dr. Figlin, Deputy Director, Integrated Oncology Service Line, Samuel Oschin Comprehensive Cancer Institute, shares how checkpoint inhibitors are changing the way RCC is treated
Robert Figlin, MD, discusses sequencing when treating metastatic RCC patients
Dr. Figlin, Deputy Director, Integrated Oncology Service Line, Samuel Oschin Comprehensive Cancer Institute, describes the process of sequencing when treating metastatic RCC patients
Robert Figlin, MD, on choosing the most appropriate treatment algorithm for metastatic RCC patients
Dr. Figlin, Deputy Director, Integrated Oncology Service Line, Samuel Oschin Comprehensive Cancer Institute, elaborates on how he stratifies metastatic RCC patients in order to choose the most appropriate treatment algorithm
Robert Figlin, MD, offers his opinion on interesting abstracts at ASCO 2017 related to RCC
Dr. Figlin, Deputy Director, Integrated Oncology Service Line, Samuel Oschin Comprehensive Cancer Institute, shares which abstracts presented at ASCO 2017 are most intriguing to him in the world of RCC
Robert Figlin, MD, speculates on the changing landscape of RCC treatment
Dr. Figlin, Deputy Director, Integrated Oncology Service Line, Samuel Oschin Comprehensive Cancer Institute, on which areas of RCC will impact the treatment landscape in the next few years
Nevena Damjanov, MD, comments on identifying subgroups of patients for targeted therapies in HCC
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, on whether or not we can reliably identify subgroups of patients for targeted therapies in HCC
Nevena Damjanov, MD, on the Phase 3 Checkpoint 459 trial studying nivolumab in HCC
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, on what she hopes to learn from the large Phase 3 Checkpoint 459 Trial studying nivolumab in advanced HCC
Nevena Damjanov, MD, shares her impressions of lenvatinib data in 1st line uHCC presented at ASCO
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, comments on the lenvatinib data presented at ASCO in the 1st line uHCC
Lyudmila Bazhenova, MD, on the progress being made towards successfully sequencing ALK inhibitors
Dr. Bazhenova, Medical Oncologist, Professor of Medicine, UC San Diego Health, describes the concerted efforts being made towards sequencing ALK inhibitors and what physicians can expect from sequencing
Lyudmila Bazhenova, MD, on treating ALK+ lung cancer patients with ALK inhibitors
Dr. Bazhenova, Medical Oncologist, Professor of Medicine, UC San Diego Health, elaborates on the outcomes physicians can expect when treating ALK+ lung cancer patients with ALK inhibitors
Lyudmila Bazhenova, MD, on differentiating between ALK inhibitors
Dr. Bazhenova, Medical Oncologist, Professor of Medicine, UC San Diego Health, explains how to differentiate ALK inhibitors and how to choose one over the other
Lyudmila Bazhenova, MD, speaks to the reliability and accuracy of ALK biomarkers
Dr. Bazhenova, Medical Oncologist, Professor of Medicine, UC San Diego Health, considers whether or not ALK biomarkers are reliable and if physicians can trust that the test is accurate
Aref Al-Kali, MD, on how hematologists will adopt midostaurin for FLT3+ AML patients
Dr. Al-Kali, Acute Leukemia and Chronic Myeloid Disorders, Mayo Clinic, provides opinion on how quickly hematologists will adopt the recently approved midostaurin for FLT3+ AML patients
Aref Al-Kali, MD, on the data coming out of ASCO 2017 regarding FLT3 mutant AML patients
Dr. Al-Kali, Acute Leukemia and Chronic Myeloid Disorders, Mayo Clinic, describes important data being presented at ASCO on FLT3 mutant AML patients and the ongoing trials for this patient population
Aref Al-Kali, MD, offers perspective on treating elderly AML patients
Dr. Al-Kali, Acute Leukemia and Chronic Myeloid Disorders, Mayo Clinic, elaborates on the challenges in treating elderly AML patients and presentations from ASCO 2017 addressing the elderly AML patient population
Nevena Damjanov, MD, discusses new agents being studied for treatment of advanced HCC
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, discusses what new agents being studied for advanced HCC will be integrated into the treatment of HCC
Andrew Norden, MD, on how Watson for Clinical Trial Matching (CTM) operates
Dr. Norden, Deputy Chief Health Officer, IBM Watson Health, explains how Watson for Clinical Trial Matching (CTM) successfully matches cancer patients to open clinical trials.
Jack West, MD, discusses PD-L1/PD-1 therapy in lung cancer treatment algorithms
Dr. West, Swedish Cancer Institute, Medical Director, Thoracic Oncology Program discusses how anti-PD-L1/PD-1 therapy has been incorporated into lung cancer treatment algorithms.
Patrick Cobb, MD, on how clinical trials improve care and contribute a revenue stream
Dr. Cobb, Medical Director, St. Vincent Frontier Cancer Center, comments on how clinical trials are able to help physicians take better care of patients and contribute to a revenue stream
Skip Burris, MD, on the impact of OCM on large community practices
Dr. Burris, President, Clinical Operations, Sarah Cannon, comments on the impact of OCM on large community practices and, specifically, those with high participation rate in clinical trials
Lucio Gordan, MD, offers recommendations for practices to improve clinical trial participation
Dr. Gordan, Florida Cancer Specialists and Research Institute, shares his thoughts on how practices can improve participation in clinical trials, and how they can turn clinical trials into a revenue stream
